WO2009114462A3 - Administration locale d'agents chimiothérapeutiques à des métastases squelettiques - Google Patents

Administration locale d'agents chimiothérapeutiques à des métastases squelettiques Download PDF

Info

Publication number
WO2009114462A3
WO2009114462A3 PCT/US2009/036512 US2009036512W WO2009114462A3 WO 2009114462 A3 WO2009114462 A3 WO 2009114462A3 US 2009036512 W US2009036512 W US 2009036512W WO 2009114462 A3 WO2009114462 A3 WO 2009114462A3
Authority
WO
WIPO (PCT)
Prior art keywords
skeletal metastases
chemotherapeutic agents
local delivery
prevention
treatment
Prior art date
Application number
PCT/US2009/036512
Other languages
English (en)
Other versions
WO2009114462A2 (fr
Inventor
John J. Barry
Robert K. Heck
Original Assignee
Inmotion Musculoskeletal Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmotion Musculoskeletal Institute filed Critical Inmotion Musculoskeletal Institute
Publication of WO2009114462A2 publication Critical patent/WO2009114462A2/fr
Publication of WO2009114462A3 publication Critical patent/WO2009114462A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne le domaine du traitement du cancer dans des structures anatomiques telles que le squelette humain. Plus spécifiquement, la présente invention porte sur l'administration locale d'agents chimiothérapeutiques utiles pour le traitement et la prévention de la douleur osseuse associée aux métastases squelettiques, la prévention de la croissance ou de la progression de métastases squelettiques, et la prévention et le traitement de fractures pathologiques provoquées par les métastases squelettiques. L'invention porte également sur un procédé de traitement de l'os chez un patient souffrant de métastases squelettiques.
PCT/US2009/036512 2008-03-11 2009-03-09 Administration locale d'agents chimiothérapeutiques à des métastases squelettiques WO2009114462A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3570908P 2008-03-11 2008-03-11
US61/035,709 2008-03-11

Publications (2)

Publication Number Publication Date
WO2009114462A2 WO2009114462A2 (fr) 2009-09-17
WO2009114462A3 true WO2009114462A3 (fr) 2009-12-23

Family

ID=41065778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/036512 WO2009114462A2 (fr) 2008-03-11 2009-03-09 Administration locale d'agents chimiothérapeutiques à des métastases squelettiques

Country Status (1)

Country Link
WO (1) WO2009114462A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007137653A1 (fr) * 2006-05-26 2007-12-06 Baxter International Inc. Composition de fibrine injectable pour augmentation osseuse

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007137653A1 (fr) * 2006-05-26 2007-12-06 Baxter International Inc. Composition de fibrine injectable pour augmentation osseuse

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INOUE, K. ET AL.: "EFFECT OF COMBINATION THERAPY WITH A NOVEL BISPHOSPHONATE, MINODRONATE(YM529), AND DOCETAXEL ON A MODEL OF BONE METASTASIS BY HUMAN TRASITIONAL CELL CARCINOMA.", CLINCAL CANCER RESEARCH, vol. 11, no. 18, 2005, pages 6669 - 6677 *

Also Published As

Publication number Publication date
WO2009114462A2 (fr) 2009-09-17

Similar Documents

Publication Publication Date Title
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
WO2008100384A3 (fr) Antagonistes de l'activine-actriia et utilisations pour la promotion de la croissance osseuse chez les patients cancéreux
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
WO2009100716A3 (fr) Produits implantables contenant des nanoparticules
WO2008023063A3 (fr) Traitement de maladies du cartilage
PL2249816T3 (pl) Preparat i sposób zapobiegania i leczenia przerzutów do kości i innych chorób kości
WO2009066283A3 (fr) Effets du corail à médiation par le calcium et procédés d'utilisation correspondants
WO2008013987A3 (fr) Pipérazinylméthylquinazolinones et azépanylméthylquinazolinones à substitution n-alkyle
MX2009011878A (es) Compuestos antagonistas de acido ribonucleico para la modulacion de beta-catenina.
WO2011065800A3 (fr) Dérivé de pyrimidine, procédé de préparation de ce dérivé et composition pharmaceutique contenant ce dérivé
GB2483419A (en) Formulations for the treatment of deep tissue pain
WO2009125925A3 (fr) Peptides imitant le facteur de croissance et utilisations de ces derniers
WO2007076087A3 (fr) Quinazolones d'aryle substitue et leurs utilisations
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
WO2014110353A9 (fr) Substrats biocompatibles liés à un ligand de notch et leur utilisation dans la formation osseuse
UA99818C2 (ru) Лечение заболеваний хряща
EA201200428A1 (ru) Композиция и способ для лечения ожирения
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
TW200628168A (en) Use of organic compounds
WO2009114462A3 (fr) Administration locale d'agents chimiothérapeutiques à des métastases squelettiques
WO2007146375A3 (fr) Composés de pyrimido-dione-quinoléine hautement solubles et procédés de traitement du cancer
WO2008130321A3 (fr) Nouveaux composés 807

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09719457

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09719457

Country of ref document: EP

Kind code of ref document: A2